Close Menu

intellectual property

The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.

The patent, called “Fragment Complementation Assays for G Protein-Coupled Receptors and Their Signaling Pathways,” solidifies Odyssey’s position in complex-based assays, and adds depth to its IP coverage in these two areas, an Odyssey official told CBA News this week.

Pages

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.